Smart Equity Invest

← Results dashboard

Q2 FY27 · NSE: SOLARA

Solara Active Pharma Sciences

Results filed 16 October 2026 · Market cap ₹3,070 crore · PE 64.9

TurnaroundGuidance maintainedTranscript read

Revenue
+33.1%
on a year ago
EBITDA
+121.2%
on a year ago
Profit to shareholders
Back to profit
from a loss a year ago
EBITDA margin
18.4%
+2.2 pts on last quarter

Solara delivered strong Q2 FY27 operating performance with consolidated revenues up 33% YoY to ₹418 crore and PAT turning positive to ₹28.5 crore on operating cost discipline and narrowing Ibuprofen EBITDA losses. However, the strategic review regarding the mothballed Vizag facility was postponed by another 12 weeks, and gross margins remained compressed by ~200 bps YoY due to geopolitical input cost pressures. Working capital intensity rose sharply, led by a large increase in trade receivables—including heightened exposure to related party Strides—which pushed net debt up sequentially by ₹20 crore.

Solara Active Pharma Sciences Limited, Q2 FY27₹ crore, consolidated
Q2 FY27Q1 FY27vs previous quarterQ2 FY26vs a year ago
Revenue417382+9.4%314+33.1%
Operating profit (EBIT)50.235.26+42.4%10.24+390.2%
Operating margin12.0%9.2%+279 bps3.3%+876 bps
Other income0.542.69−79.9%0.49+10.2%
Exceptional items−4.50–0–
Profit before exceptional items and tax32.9616.31+102.1%−10.1n.m.
Profit to shareholders28.4616.31+74.5%−10.1n.m.
Earnings per share (₹)5.923.52+68.2%-2.36n.m.

Source: Solara Active Pharma Sciences Limited’s filing to NSE, 16 October 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.

What stood out

  • Delivered best operating profitability in five years, turning profitable at PAT level
    SourceQ2 FY27 has been our best quarter in about five years... revenue grew 33% year-on-year to INR418 crores. EBITDA more than doubled to INR77 crores, up 118%. And PAT was at INR28.5 crores against a loss of around INR10 crores (Sandeep Rao, Original Page 3).
  • Ibuprofen segment reached near-breakeven at EBITDA level, reversing steep losses
    SourceThe EBITDA loss has narrowed. You can see we are almost breakeven compared to the roughly INR9 crores loss that we had in Q1. The business is now close to breakeven from a loss margin of around 21% just two quarters ago (Sandeep Rao, Original Page 3).
  • Strategic review of Ibuprofen business delayed by another 12 weeks
    SourceThis process is taking us time. We estimate that we will be able to close this in 12 weeks. So we will come back to you with an update on the outcome of the review and the next steps... in a period of 12 weeks (Sandeep Rao, Original Page 4).
  • Net debt reduced to ~₹500 crore from ~₹614 crore in March 2026, though up ₹20 crore sequentially
    SourceWe have been able to reduce net debt to close to INR500-odd crores from INR614-odd crores, which was there as on March '26. Of this reduction, INR100-odd crores came from the rights issue money, balance INR14 crores was from the operational cash flows... sequential basis, the net debt has moved up by close to INR20-odd crores as compared to June '26 (Sarat Kumar, Original Page 5).

Guidance

MetricGuidancePeriod
Annual Capex
SourceWe are close to committing to close to INR40 crores, INR50-odd crores of capex on a yearly basis. So out of that, on an average, every quarter, we normally spend close to INR10 crores to INR15 crores (Sarat Kumar, Original Page 8).
INR 40 to 50 crores per year (~INR 10 to 15 crores per quarter)Annual / FY27
DMF Filings
SourceThis year, we believe that we can do five DMF filings. We've done one last quarter. We've done one this quarter, and I'm hopeful that we can do three more by the end of this financial year (Sandeep Rao, Original Page 9).
5 DMF filings in FY27 (3 more to be filed in H2)FY27
Base Business Gross Margin
SourceWe have been always maintaining that we are very comfortable to sustain a gross margin of close to 52% to 55% kind of a range (Sarat Kumar, Original Page 9).
52% to 55%Medium to long term
Net Debt to EBITDA Multiple
SourceNet Debt to EBITDA ratio multiple has actually improved to close to 1.8x as compared to 3.2x what we had last year. And this is something we should be able to be in the similar range over the medium term (Sarat Kumar, Original Page 5).
~1.8xMedium term
Ibuprofen Strategic Review Completion
SourceWe estimate that we will be able to close this in 12 weeks. So we will come back to you with an update on the outcome of the review and the next steps (Sandeep Rao, Original Page 4).
Conclude within 12 weeksNext 12 weeks

The timeline to conclude the strategic review of the Ibuprofen business was extended by 12 weeks after management had earlier indicated it would be resolved in Q2.

Tailwinds

  • Base business revenue grew 37% YoY to ₹327 crore with healthy margins
    SourceRevenue grew 37% year-on-year to INR327 crores, staying above the INR300 crores number for the third quarter in a row. EBITDA grew 68% to INR77 crores, with the margin up about 440 basis points to 23.6% (Sandeep Rao, Original Page 3).
  • Operating leverage through stable fixed opex base
    SourceOn the operating cost front, we have been able to sustain our cost base roughly around INR120-odd crores, which is predominantly flat over the previous few quarters, hence, enabling the incremental gross margin flow through to the EBITDA (Sarat Kumar, Original Page 5).
  • Regulatory clearances achieved for Cuddalore and Mangalore facilities
    SourceOur Mangalore facility successfully completed an ANVISA audit in August. If you recollect, we had a successful ANVISA audit of our Cuddalore facility in May (Sandeep Rao, Original Page 4).
  • Lower finance costs following debt paydown
    SourceDepreciation was close to INR266 million... net finance cost has actually dropped by close to INR32 million as compared to previous quarters, and that's a reduction of roughly 16% and that has resulted because of a reduction of debt (Sarat Kumar, Original Page 5).

Headwinds

  • West Asia crisis disrupting raw materials and pressuring gross margins
    SourceGross margin came at a 47.2%... slightly lower by roughly 200 basis points as compared to last year, which was predominantly driven by incremental raw material costs as well as input costs driven due to the West Asia crisis (Sarat Kumar, Original Page 4).
  • Inability to fully pass on cost increases to customers
    SourceSo most this GM dip of 3% something, although we are having an effort to have that price increase passed on, but we are not able to pass on to customers at every stage or, say, with every customer and every product (Sarat Kumar, Original Page 12).
  • Sequential rise in net debt due to working capital lock-in and shipping delays
    SourceSequential basis, the net debt has moved up by close to INR20-odd crores as compared to June '26, since we had invested in additional working capital to sustain the sustained growth in the business as well as some sort of maintenance capex (Sarat Kumar, Original Page 5).
  • Exceptional loss on sale of idle Vizag equipment
    SourceWe have recorded an exceptional loss item of INR45 million, which was predominantly because of unutilized equipment lying at our Vizag facility, which we have sold (Sarat Kumar, Original Page 5).

New businesses and products

capacity expansion · Under evaluation; review extended by 12 weeks

Strategic restructuring or repurposing of Ibuprofen facility (Vizag)

Expected benefit
Either repurposing into a multi-product facility (including captive intermediates) or monetizing via a sale to a buyer
Risks
Continued losses if commodity ibuprofen pricing softens again; execution delays in closing review
Timeline
Outcome expected in 12 weeks (Q3 FY27)
Investment
Already incurred INR 182 crores on Vizag project per annual report; INR 4.5 crore idle equipment sold as exceptional loss
SourceOne is repurposing the plant from being a single product dedicated facility into a multiproduct facility... And of course, the other option is the internal option of finding an appropriate buyer... We estimate that we will be able to close this in 12 weeks (Sandeep Rao, Original Page 4, 6).

new product · Filed 2 DMFs year-to-date; 3 more planned

DMF filing pipeline acceleration (including Valbenazine)

Expected benefit
Longer-term pipeline replenishment with high-margin complex APIs
Risks
Patent litigation, regulatory approval timelines, customer qualification timing
Timeline
Total of 5 DMF filings targeted within FY27
SourceThis year, we believe that we can do five DMF filings. We've done one last quarter. We've done one this quarter, and I'm hopeful that we can do three more by the end of this financial year (Sandeep Rao, Original Page 9).

Things to check

  • Exceptional items of ₹-4.5 crore in 2026-09
  • Sharp increase in trade receivables to ₹506 crore, driven significantly by related party Strides
    SourceReceivables from Strides have increased from INR63 crores to INR160 crores... receivables in Q2 FY '27 is around, I think, INR506 crores (Kushal Goenka, Original Page 8).
  • Uncertain asset value of ₹182 crore Vizag project amid sale of equipment at an exceptional loss
    SourceWe have recorded an exceptional loss item of INR45 million, which was predominantly because of unutilized equipment lying at our Vizag facility, which we have sold... CWIP at Vizag, which is purely one-off (Sarat Kumar, Original Page 5, 6).

How the call went

Management presented strong headline numbers and operating cost control, but faced persistent questioning regarding the delayed decision on the mothballed Vizag Ibuprofen facility and a substantial surge in trade receivables, especially from related party Strides.

Specific or vague
Management shared clear segment metrics, price vs volume breakdown, and procurement geographical mix, but declined specific product-level details on DMFs and volume numbers.
Candour
Management was candid about gross margin pressure from the West Asia crisis and openly acknowledged the delay in the Ibuprofen strategic review, but gave general responses on receivable buildup.
The hard questions
Analysts probed heavily on the delayed Ibuprofen decision, the massive surge in trade receivables (over fourfold YoY), related-party receivables from Strides, and potential asset write-downs at Vizag.

What analysts pressed on

  • Substantial delay in deciding the fate of the Vizag plant / Ibuprofen business after multiple quarters of review
  • Sharp jump in trade receivables to ~₹506 crores, particularly rising exposure from related party Strides (from ₹63 cr to ₹160 cr)
  • Sustainability of the Ibuprofen gross margin recovery and risk of reverting to quarterly operating losses of ₹10-15 crores once competitors' supply issues resolve
  • Gross margin compression in the base business due to raw material and freight inflation

Answers that sidestepped

  • Deflected specific questions on the customer dynamics, target market size, and sole-supplier status for the newly filed Valbenazine DMF, stating it would be taken offline.
  • Offered generalised operational reasons (back-ended billing and container issues) rather than detailed customer-level reasons when questioned on the massive surge in trade receivables from Strides.

Numbers against the story

Management emphasized that Q2 FY27 was its best quarter in five years with strong operating leverage and an EBITDA turnaround in Ibuprofen. However, the reported numbers reveal that gross margins contracted ~200 bps YoY across the consolidated business to 47.2% due to input inflation, working capital expanded (driving net debt up by ₹20 crore sequentially), and trade receivables surged over fourfold YoY, dampening the cash conversion quality of the reported profit.

Sources

  • Concall transcript · filed 23-Oct-2026
  • Figures: the company’s results filing with NSE, linked under the table.

Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.